PT1214091E - Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina - Google Patents

Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina

Info

Publication number
PT1214091E
PT1214091E PT00961900T PT00961900T PT1214091E PT 1214091 E PT1214091 E PT 1214091E PT 00961900 T PT00961900 T PT 00961900T PT 00961900 T PT00961900 T PT 00961900T PT 1214091 E PT1214091 E PT 1214091E
Authority
PT
Portugal
Prior art keywords
chronic renal
antaginists
integrin
therapies
renal insufficiency
Prior art date
Application number
PT00961900T
Other languages
English (en)
Inventor
Allen Andrew
Pusey Charles
Lobb Roy
Original Assignee
Imperial College
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College, Biogen Idec Inc filed Critical Imperial College
Publication of PT1214091E publication Critical patent/PT1214091E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Gastroenterology & Hepatology (AREA)
PT00961900T 1999-09-14 2000-09-14 Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina PT1214091E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15382699P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
PT1214091E true PT1214091E (pt) 2006-09-29

Family

ID=22548902

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00961900T PT1214091E (pt) 1999-09-14 2000-09-14 Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina

Country Status (13)

Country Link
US (3) US20030007969A1 (pt)
EP (1) EP1214091B1 (pt)
JP (3) JP4975922B2 (pt)
AT (1) ATE325623T1 (pt)
AU (1) AU783266B2 (pt)
CA (1) CA2384948C (pt)
CY (1) CY1105117T1 (pt)
DE (1) DE60027907T2 (pt)
DK (1) DK1214091T3 (pt)
ES (1) ES2263485T3 (pt)
NZ (1) NZ517781A (pt)
PT (1) PT1214091E (pt)
WO (1) WO2001019396A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1506359A (zh) 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
US7767219B2 (en) 2003-01-31 2010-08-03 Boston Scientific Scimed, Inc. Localized drug delivery using drug-loaded nanocapsules
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
DE102009000854A1 (de) * 2009-02-13 2010-08-19 Ernst-Moritz-Arndt-Universität Greifswald Osteopontin-Rezeptor-Liganden zur Behandlung des chronischen Nierenversagens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111657A (en) * 1977-01-21 1978-09-05 American Monitor Corporation Creatinine assay and reagent system
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
EP0670735B1 (en) * 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
EP0678122B1 (en) * 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
EP0682529B2 (en) * 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
NZ333904A (en) * 1996-07-25 2000-06-23 Biogen Inc VLA-4 and IIb/IIIa cell adhesion inhibitors
WO1999061040A2 (en) * 1998-05-22 1999-12-02 Boys Town National Research Hospital USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE
PL203114B1 (pl) * 1998-09-14 2009-08-31 Regents Board Of Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6245885B1 (en) * 1998-10-05 2001-06-12 Mcgill University Bax-mediated apoptosis modulating reagents and methods
EP2140881B1 (en) * 1999-12-16 2013-04-17 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists

Also Published As

Publication number Publication date
ATE325623T1 (de) 2006-06-15
CA2384948C (en) 2013-07-16
US20030007969A1 (en) 2003-01-09
US20140234299A1 (en) 2014-08-21
EP1214091B1 (en) 2006-05-10
JP2011116791A (ja) 2011-06-16
DE60027907D1 (de) 2006-06-14
DK1214091T3 (da) 2006-08-28
ES2263485T3 (es) 2006-12-16
NZ517781A (en) 2004-01-30
JP5463316B2 (ja) 2014-04-09
CA2384948A1 (en) 2001-03-22
JP4975922B2 (ja) 2012-07-11
JP2003509380A (ja) 2003-03-11
EP1214091A1 (en) 2002-06-19
AU7379200A (en) 2001-04-17
DE60027907T2 (de) 2007-01-04
WO2001019396A1 (en) 2001-03-22
AU783266B2 (en) 2005-10-06
US20110305686A1 (en) 2011-12-15
CY1105117T1 (el) 2010-03-03
JP2013116916A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
RS20050035A (en) Therapies for renal failure using interferon-betha
PT910400E (pt) Terapias para insuficiencia renal cronica
BR9913645A (pt) Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
TR199901361T2 (xx) S�lfonamid t�revleri, haz�rlanma prosesi ve ila� olarak kullan�mlar�
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
DK1098874T3 (da) Benzocycloheptener, fremgangsmåder til deres fremstilling, farmaceutiske præparater, som indeholder disse, samt deres anvendelse til fremstilling af lægemidler
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
BR9803168A (pt) Tratamento de parada cardìaca congestiva.
WO2004019876A3 (en) Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
ITMI20000300A0 (it) Nebulizzatore medico per liquido da utilizzare nella terapia respiratoria e altre applicazioni
NO993066L (no) Ny behandling for leddinflammasjon
NO20052059L (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
PT1214091E (pt) Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina
PT980252E (pt) Terapias para insuficiencia renal aguda
DE69633396D1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
Hosie et al. The topical NSAID felbinac versus oral NSAIDS: a critical review.
ATE361756T1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4 protease
BR9713514A (pt) Novo uso de creatina
TR200102930T2 (tr) Ruhsal bozuklukların tedavisinde yararlı olan ilaçların üretiminde osanetat kullanımı
AR023464A1 (es) Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados
WO2002029031A3 (en) Isoprenoid-dependent ras anchorage (idra) proteins
Manniche et al. Re: Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low back pain: a systematic review within the framework of the Cochrane collaboration. Spine 2003; 28: 1978-92